Evidence map›Paper›PMID 24627635›Full record

ArticleNeuropsychiatric disease and treatment2014

Effect of the coadministration of citalopram with mirtazapine or atipamezole on rat contextual conditioned fear.

Takahiro Masuda, Takeshi Inoue, Yan An, Naoki Takamura, Shin Nakagawa, Yuji Kitaichi, Tsukasa Koyama, Ichiro Kusumi

Open access · goldAbstract read
In one paragraph

Article in Neuropsychiatric disease and treatment, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Takahiro MasudaDepartment of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo Japan ; Medical Affairs, Dainippon Sumitomo Pharma, Co, Ltd, Tokyo, Japan.
Takeshi InoueDepartment of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo Japan.
Yan AnDepartment of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo Japan.
Naoki TakamuraDepartment of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo Japan ; Regenerative and Cellular Medicine Office, Dainippon Sumitomo Pharma, Co, Ltd, Osaka, Japan.
Shin NakagawaDepartment of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo Japan.
Yuji KitaichiDepartment of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo Japan.
Tsukasa KoyamaDepartment of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo Japan.
Ichiro KusumiDepartment of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo Japan.
Hokkaido University · JPSumitomo Dainippon Pharma (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMirtazapine, a noradrenergic and specific serotonergic antidepressant, which blocks the α2-adrenergic autoreceptors and heteroreceptors, has shown anxiolytic properties in clinical trials and preclinical animal experiments. The addition of mirtazapine to selective serotonin reuptake inhibitors (SSRIs) is clinically suggested to be more effective for anxiety disorders. In this study, we examined the combined effects of mirtazapine and citalopram, an SSRI, on the freezing behavior of rats, which was induced by contextual conditioned fear as an index of anxiety or fear.

methodsMale Sprague Dawley rats individually received footshocks in a shock chamber, and 24 hours later, they were given citalopram and/or mirtazapine injections. One hour after citalopram and 30 minutes after mirtazapine administration, freezing behavior was analyzed in the same shock chamber without shocks.

resultsMirtazapine decreased freezing in a dose-dependent manner, which is consistent with a previous report; it also enhanced an anxiolytic-like effect at a high dose (30 mg/kg) of citalopram. Because mirtazapine blocks α2-adrenoreceptors, the combined effect of atipamezole, a selective α2 receptor antagonist, with citalopram was also examined. Similar to mirtazapine, atipamezole reduced freezing dose-dependently, but the enhancement of citalopram's effects by atipamezole was not clear when compared with mirtazapine.

conclusionThe present findings suggest that mirtazapine has an anxiolytic-like effect and may enhance the anxiolytic-like effect of SSRIs, but this enhancement may not be explained by its anti-α2 property alone.

Indexed as

anxietyconditioned fearmirtazapineselective serotonin reuptake inhibitorα2-adrenoreceptor

Identifiers

PMID24627635
PMCPMC3931693
OpenAlexW2147302393

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.